GUFIC BIOSCIENCES LTD.

Manufactures and markets pharmaceutical formulations across critical care, women's health, and aesthetics, alongside bulk drugs (APIs). In the segment data for the year-to-date period ending September 2018, the Pharma (formulations) stream was 92.4% of segment revenue at ₹159.06 cr with EBIT of ₹29.11 cr, while Bulk Drugs was 7.1% at ₹12.15 cr. Operating scale includes a lyophilised injectables plant at Indore that reached 30% capacity utilisation and EBITDA breakeven in Q4 FY26, with 40 tech transfers completed, 27 in the pipeline, 200+ state FDA approvals, and an EU GMP certificate pending from a December 2025 audit. The international business is shifting from distributor-held to in-house marketing authorisations via an Ireland-based subsidiary, with new approvals in Myanmar, Philippines, South Africa, Colombia, Germany and Ecuador, and a global-health partnership covering 109 countries. On the domestic side, the women's health franchise holds category leadership in Ferticare and recorded its strongest year in gonadotropins; the aesthetics franchise sits at #2 in Indian botulinum toxin with ~23% share (~3.5-4% of revenue), and a Canadian filler/biostimulator in-licensing deal targets a Q3-Q4 FY27 launch. Q4 FY26 revenue was ₹252 cr (the strongest quarter on record); full-year FY26 revenue was ₹940.5 cr (+14.7% YoY) with EBITDA margin at 16.26%. Materials are the largest cost at 45.1% of revenue, followed by employee cost (16.1%), other opex (23.3%) and depreciation (3.3%). Gross debt sits around ₹400 cr against ~₹75 cr cash, with ₹20 cr per year of replacement capex and no greenfield spend planned for the next two years.